Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)

BACKGROUND. GSK3532795 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor that targets HIV-1 Gag, inhibiting the final protease cleavage between capsid protein p24 and spacer protein-1, producing immature, noninfectious virions. METHODS. This was a phase 2a, rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Carey, Schürmann, Dirk, Sobotha, Christian, Boffito, Marta, Sevinsky, Heather, Ray, Neelanjana, Ravindran, Palanikumar, Xiao, Hong, Keicher, Christian, Hüser, Andreas, Krystal, Mark, Dicker, Ira B., Grasela, Dennis, Lataillade, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848258/
https://www.ncbi.nlm.nih.gov/pubmed/28369211
http://dx.doi.org/10.1093/cid/cix239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848258/
https://www.ncbi.nlm.nih.gov/pubmed/28369211
http://dx.doi.org/10.1093/cid/cix239

Ejemplares similares